论文部分内容阅读
目的：观察微粒化非诺贝特的降血脂疗效及是否有改善血液流变性的作用。方法：６７例原发性高脂血症病人（男性５１例，女性１６例；年龄５４ａ±ｓ１１ａ）给微粒化非诺贝特２００ｍｇ，ｐｏ，ｑｎ，疗程８ｗｋ。结果：治疗８ｗｋ后血清三酰甘油、总胆固醇、低密度脂蛋白胆固醇和载脂蛋白Ｂ１００显著低于治疗前水平（Ｐ＜０．０１或Ｐ＜０．０５），高密度脂蛋白胆固醇与载脂蛋白ＡＩ升高，（Ｐ＜０．０５）；另外血浆粘度、凝血因子Ｉ、血小板粘附率和血细胞比容较治疗前明显下降（Ｐ＜０．０１或Ｐ＜０．０５）。结论：微粒化非诺贝特能有效降低高血脂，同时明显改善了病人的高粘血症。
Objective: To observe the anti-hyperlipidemic efficacy of micronized fenofibrate and its effect on improving hemorrheology. Methods: 67 patients with primary hyperlipidemia (male 51, female 16; age 54a ± s11a) were given micronized fenofibrate 200 mg, po, qn for 8 weeks. Results: Serum triglyceride, total cholesterol, low density lipoprotein cholesterol, and apolipoprotein B100 were significantly lower than those before treatment (P <0.01 or P <0.05) after 8 weeks of treatment. The levels of high density lipoprotein cholesterol (P <0.05). In addition, plasma viscosity, coagulation factor I, platelet adhesion rate and hematocrit decreased significantly compared with before treatment (P <0.01 or P <0.05). Conclusion: The micronized fenofibrate can effectively reduce hyperlipidemia and significantly improve the patient’s hyperviscosity.